10 results about "IMMUNOLOGIC DEFICIENCY" patented technology

This disclosure provides IL-15 fusion proteins and compositions comprising IL-15 fusion proteins. This disclosure further provides methods for treating and / or preventing immunodeficiency in subjects, as well as methods for cancer immunotherapy, which include administering fusion proteins as described herein.

The invention relates to an efficient energy supply type laboratory mouse feed which comprises the following components in percentage by weight: 20-40% of corn, 10-30% of wheat, 1-5% of wheat middling, 4-10% of soybean meal, 2-8% of fish meal, 2-6% of chicken meal, 1-10% of soybean hull, 1-5% of soybean oil, 1-5% of lard, 0.5-2% of stone powder, 0.5-1.5% of calcium hydrophosphate, 2-5% of premix, 1-5% of MCT microcapsule powder and 0.5-2% of glutamine. The stability of MCT is improved through a microencapsulation method, the activity of glutamine is reserved through an embedding method, the synergistic effect of MCT microcapsule powder and glutamine is utilized, meanwhile, lard oil and fat raw materials are added, high-temperature steam is used for curing materials in the production process, the fragrance of the feed is further improved, the palatability of the feed is jointly improved, the food intake of laboratory mice is not affected, and the production cost is reduced. The utilization efficiency of the feed is improved; the experimental mouse feed can reduce body fat and improve blood lipid level, can effectively prolong exhaustion time of mice, and is suitable for cultivation and maintenance of special experimental animals such as intestinal injury models and immunodeficiency models.

The present disclosure is directed to a method of treating a CTLA-4 checkpoint associated immunodeficiency by administering a therapeutically effective amount of a pharmaceutical composition comprising 1H-indole-3-carboxaldehyde (3-IAld) or 1-methylindole-3-carboxylic acid.

The invention discloses a cholate synergistic effect-based open wound medicine formula and a preparation method thereof, cholate and sodium chloride are subjected to high-pressure homogenization and grinding to nanoscale, acetic acid, water and alcohol are sequentially added, after pH is adjusted, terminal filtration is carried out through a 0.22-micron filter membrane, sterility is ensured, the formula can penetrate into a corium layer to inhibit inflammatory factors (such as TNF-alpha), and the open wound medicine has a good application prospect. And an epidermal cell migration signal (such as TGF-beta 1) is activated, so that the healing period is shortened to 8-10 days. The nano-scale dispersion improves the medicine permeation efficiency, the weak acid environment inhibits the formation of a gram-positive bacterium biofilm, and the eye drops are free of sensitization, are suitable for immunodeficiency patients and have auxiliary effects on haemorrhoids and eye diseases.

The present invention relates to an immunodeficient non-human animal where endogenous drug metabolising enzymes and transcription factors are substantially inactivated. In some aspects of the invention, the animal expresses human drug metabolising enzymes and associated transcription factors. There is also provided related methods of generating the animal of the invention. Additionally, there is provided methods of performing preclinical drug studies using the animal of the invention.

The present disclosure provides IL-15 fusion proteins and compositions comprising the IL-15 fusion proteins. Specifically, the fusion protein comprises at least one of an IL-15R alpha sequence and / or an IL-15 sequence fused with an albumin protein. The disclosure also provides methods of treating and / or preventing immunodeficiency and methods for immunotherapy of cancer in a subject, wherein the methods comprise administering the fusion protein described herein.

The present disclosure relates methods for treating skin disorders caused by an immune deficiency with oral formulations comprising 1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (Compound I) or pharmaceutically acceptable derivative thereof. In particular, the oral formulations described herein may be used to treat atopic dermatitis.

The invention belongs to the technical field of model animal preparation, and particularly relates to a pulmonary aspergillosis rat model construction method based on tracheal inoculation under laryngoscope direct view and application thereof. According to the invention, standardized immunosuppression is carried out on rats by using cyclophosphamide, and an immunodeficiency state conforming to a disease basis can be stably and repeatedly induced. Based on direct sight of the laryngoscope, the glottis structure of the rat is clear and visible, and the intubation process is visual and controllable. The technical threshold is obviously reduced, and the success rate and the operation repeatability of a beginner are improved; the method has the advantages that laryngeal injury and mistaken inoculation are avoided to the greatest extent, it is guaranteed that bacterial liquid is accurately fed into the trachea, neck operation wounds are avoided, non-specific inflammation interference is reduced, the uniformity, stability and repeatability of a model are improved, and the modeling success rate reaches 100%. The invention provides a disease research platform which is standardized, quantifiable, high in quality and highly associated with clinic, and can be used for screening the pulmonary aspergillosis treatment medicines and evaluating the effectiveness of the pulmonary aspergillosis treatment medicines.

The present disclosure relates to methods for producing mature oocytes comprising transplanting ovarian tissue or any fragment thereof of a human female into at least one recipient site of an immunodeficient rabbit, and collecting mature oocytes from said transplanted ovarian tissue. In addition, the methods comprises providing conditions for follicles development and oocytes maturation in said rabbit.

The invention discloses a method for pre-activating neutrophil based on microfluid shear stress, and belongs to the field of biological medicine. According to the device and the method, the micro-fluidic chip is used for constructing the flow micro-channels with the reducing structures in different appearance shapes, accurate and stable flow speed control is realized by virtue of a pneumatic perfusion system, and controllable shear stress is applied to the neutrophile granulocytes through the reducing structures of the micro-fluidic chip, so that the drug-free pre-activation of the neutrophile granulocytes is realized, and the drug-free pre-activation of the neutrophile granulocytes is realized. The antibacterial functions of chemotaxis, phagocytosis, NETs formation, ROS release and the like are directionally enhanced. The activated neutrophil can be used for treating local or systemic infection through local smearing or venous transfusion, and can be used independently or combined with antibiotics. According to the method, the bacterial clearance rate in an infection model can be remarkably increased, organ injury is relieved, and immune overreaction is regulated. The invention provides a novel cellular immunotherapy for treatment of drug-resistant bacterium infection and immunodeficiency patients, and has standardized and repeatable clinical application potential.